Miniature NIR-II Nanoprobes for Active-Targeted Phototheranostics of Brain Tumors

Human serum albumin-encapsulated near-infrared hemicyanine photosensitizers for viscosity imaging and enhanced photodynamic therapy

The research successfully developed a novel dual-function near-infrared photosensitizer, CyI, which is encapsulated with human serum albumin (HSA) to form CyI-HSA nanocomplex that can simultaneously monitor the viscosity of cancer cell and enhance the efficacy of photodynamic therapy (PDT). In vitro experiments demonstrated that compared with CyI alone, CyI-HSA has superior water solubility and high photostability, and can effectively prevent aggregation-caused quenching (ACQ) caused by π-π stacking. Additionally, singlet oxygen quantum yield of CyI-HSA as high as 27.4 % under 658 nm laser irradiation, indicating significant PDT potential. Cellular experiments further revealed that CyI-HSA can monitor intracellular viscosity with high sensitivity, while generating a substantial amount of singlet oxygen, promoting PDT and cell apoptosis. Treatment of HepG-2 cells with 1 µmol/L CyI-HSA reduced cell viability by only 13 % (Laser = 100 mW cm-2). Therefore, as a kind of nano-photosensitizer integrating diagnostic and therapeutic functions, CyI-HSA has a broad prospect in the application of near-infrared hemicyanine photosensitizers in photodynamic therapy.

Surface engineering of NIR-II luminescent gold nanoclusters for brain glioma-targeted imaging

Ultrasmall gold nanoclusters (AuNCs) with photoluminescence in the second near-infrared region (NIR-II) have emerged as promising probes for in vivo biomedical applications. However, it remains a challenge to utilize NIR-II-emitting AuNCs for imaging brain glioblastoma (GBM), which is highly lethal and hard to diagnose in time. Herein, we have presented systematic investigations on the brain delivery and GBM targeting efficacies of NIR-II-emitting AuNCs protected by different ligands. We first synthesized four types of AuNCs with surface coatings of small thiolated ligands and proteins, and then studied their in vitro penetration capability into the blood-brain barrier (BBB) and in vivo GBM targeting performances. It was found that the BBB permeability of AuNCs determined by the in vitro transwell model was not evidently affected by the surface ligands. Significantly, AuNCs protected by albumin exhibited notably extended blood circulation and less skull binding compared to those protected by small ligands, enabling superior in vivo brain GBM-targeted NIR-II PL imaging. We also modified the albumin-AuNCs with targeting peptides to improve in vivo imaging contrast. Additionally, AuNCs had negligible toxic effects on major organs as well as brain tissues and neurons, corroborating their good biocompatibility. This study examined the surface engineering of NIR-II luminescent AuNCs for brain GBM targeting, which may offer insights into the future design of AuNCs for bioapplications.

Albumin-Energized NIR-II Cyanine Dye for Fluorescence/Photoacoustic/Photothermal Multi-Modality Imaging-Guided Tumor Homologous Targeting Photothermal Therapy

Endowing cyanine dyes with hydrophilicity, long blood circulation, tumor targeting, and robust therapeutic efficacy in the second near-infrared (NIR-II) window is challenging for cancer treatment. Herein, we develop cancer cell membrane-coated albumin-NIR-II cyanine dye assemblies, denoted as LZ-1105@HAm, to optimize the photophysical properties of cyanine dyes in aqueous solution for NIR-II fluorescence (FL)/photoacoustic (PA)/photothermal (PT) multimodality imaging-guided tumor homologous targeting photothermal therapy. LZ-1105@HAm exhibits good hydrophilicity, extends the half-life of blood circulation from 0.634 ± 0.058 to 1.919 ± 0.107 h, enhances NIR-II FL/PA/PT imaging capabilities in vitro and in vivo, and improves photothermal conversion efficiency from 34.6% to 45.4%. Additionally, the cell membrane coating confers the assemblies with tumor-specific targeting capability, increasing tumor accumulation and enabling efficient photothermal tumor ablation. Upon 1064 nm laser irradiation, LZ-1105@HAm demonstrates significantly improved therapeutic efficacy. This research provides a strategy for constructing cyanine dye-based nanotheranostics with potential clinical application prospects.

A near-infrared triggered multi-functional indocyanine green nanocomposite with NO gas release function inducing improved photothermal therapy

The integration of photothermal and near-infrared (NIR) imaging capabilities of indocyanine green (ICG) small molecules has attracted considerable attention in tumor diagnosis and treatment. However, the abnormal upregulation of cellular heat shock proteins (HSPs) induced by photothermal therapy (PTT) enhances cellular heat resistance, thereby severely affecting the efficacy of PTT. In this study, to address the impact of HSPs on the efficacy of PTT while obtaining high-quality NIR fluorescence imaging in the NIR region, we designed a targeted peptide@ICG nanofluorescent probe encapsulated in liposomes. The introduced cRGD targeting peptide not only possesses tumor-targeting capabilities but also features LA as the last amino acid in the targeting peptide, which can generate nitric oxide (NO) under reactive oxygen species (ROS) triggering. It can happen under 808 nm single-light source NIR light, and the guanidine group in the peptide decomposes and combines with singlet oxygen molecules to generate NO gas molecules, thereby exerting an elevated photothermal effect by inhibiting the expression of HSP70. In addition, the nanoprobes enable deep imaging and treatment of glioma in situ and can be combined with a laser speckle contrast imaging (LSCI) system for multimodal imaging. This composite probe demonstrates synergistic tumor therapeutic effects of photodynamic therapy (PDT), PTT, and gas therapy, offering a promising strategy for cancer treatment.

High Spatiotemporal Near-Infrared II Fluorescence Lifetime Imaging for Quantitative Detection of Clinical Tumor Margins

Accurate detection of tumor margins is essential for successful cancer surgery. While indocyanine green (ICG)-based near-infrared (NIR) fluorescence (FL) surgical navigation enhances the visual identification of tumor margins, its accuracy remains subjective, underscoring the need for quantitative approaches. In this study, a high spatiotemporal fluorescence lifetime (FLT) imaging technology is developed in the second near-infrared window (NIR-II, 1000-1700 nm) for quantitative tumor margin detection, utilizing folate receptor-targeted ICG nanoprobes (FPH-ICG). FPH-ICG exhibits a significantly prolonged NIR-II FLT (750 ± 7 ps vs 260 ± 3 ps) and increased NIR-II FL brightness (FPH-ICG/ICG = 3.8). In vitro and in vivo studies confirm that FPH-ICG specifically targets folate receptor-α (FRα) on SK-OV-3 ovarian cancer cells, achieving high-contrast NIR-II FL imaging with a signal-to-background ratio of 10.8. Notably, NIR-II FLT imaging demonstrates superior accuracy (90%) and consistency in defining tumor margins compared to NIR-II FL imaging (58%) in both SK-OV-3 tumor-bearing mice and clinical tumor samples. These findings underscore the potential of NIR-II FLT imaging as a quantitative tool for guiding surgical tumor margin detection.

Recent Advances in Indocyanine Green-Based Probes for Second Near-Infrared Fluorescence Imaging and Therapy

Fluorescence imaging, a highly sensitive molecular imaging modality, is being increasingly integrated into clinical practice. Imaging within the second near-infrared biological window (NIR-II; 1,000 to 1,700 nm), also referred to as shortwave infrared, has received substantial attention because of its markedly reduced autofluorescence, deeper tissue penetration, and enhanced spatiotemporal resolution as compared to traditional near-infrared (NIR) imaging. Indocyanine green (ICG), a US Food and Drug Administration-approved NIR fluorophore, has long been used in clinical applications, including blood vessel angiography, vascular perfusion monitoring, and tumor detection. Recent advancements in NIR-II imaging technology have revitalized interest in ICG, revealing its extended tail fluorescence beyond 1,000 nm and reaffirming its potential as a clinically translatable NIR-II fluorophore for in vivo imaging and theranostic applications for diagnosing various diseases. This review emphasizes the notable advances in the use of ICG and its derivatives for NIR-II imaging and image-guided therapy from both fundamental and clinical perspectives. We also provide a concise conclusion and discuss the challenges and future opportunities with NIR-II imaging using clinically approved fluorophores.

Albumin-Chaperoned Deep-NIR Triarylmethane Dyes for High-Contrast In Vivo Imaging and Photothermal Therapy

Fluorophores absorbing/emitting in the deep near-infrared (deep NIR) spectral region, that is, 800 nm and beyond, hold great promise for in vivo bioimaging, diagnosis, and phototherapy due to deeper tissue penetration. The bottleneck is the lack of bright, stable, and readily synthesized deep NIR fluorophores. Here, it is reported that the albumin-chaperon strategy is a viable one-for-all strategy to address these difficulties. A focused library of deep-NIR absorbing dyes (EA5) is easily synthesized via a two-step cascade. They are neither very stable nor bright in phosphate buffer due to a propeller-type flexible scaffold. Through screening, EA5_c3 is found to exhibit a high affinity toward bovine serum albumin (BSA). Binding-associated structural rigidification resulted in a gigantic 26-fold fluorescence enhancement. The albumin chaperone also greatly improved the stability of EA5_c3 by shielding the bisbenzannulated triarylmethane core from nucleophilic or oxidative species. The resulting EA5_c3@BSA exhibits high biocompatibility. It offered high-resolution vasculature, lymph systems, tumors, and other tissue imaging with its bright deep NIR emission. At the same time, it exhibits prominent potential in photoacoustic imaging and photothermal treatment of subcutaneous and orthotopic breast tumors. These findings provide insights into robust and high-performance fluorophores with deep NIR regions for theranostic against aggressive cancers.

Applications of nanotheranostics in the second near-infrared window in bioimaging and cancer treatment

Achieving accurate and efficient tumor imaging is crucial in the field of tumor treatment, as it facilitates early detection and precise localization of tumor tissues, thereby informing therapeutic strategies and surgical interventions. The optical imaging technology within the second near-infrared (NIR-II) window has garnered significant interest for its remarkable benefits, such as enhanced tissue penetration depth, superior signal-to-background ratio (SBR), minimal tissue autofluorescence, reduced photon attenuation, and lower tissue scattering. This review explained the design and optimization strategies of nano-agents responsive to the NIR-II window, such as single-walled carbon nanotubes, quantum dots, lanthanum-based nanomaterials, and noble metal nanomaterials. These nano-agents enable non-invasive, deep-tissue imaging with high spatial resolution in the NIR-II window, and their superior optical properties significantly improve the accuracy, efficiency, and versatility of imaging-guided tumor treatments. And we discussed the characteristics and advantages of fluorescence imaging (FL)/photoacoustic imaging (PA) in NIR-II window, providing a comprehensive overview of the latest research progress of different nano-agents in FL/PA imaging-guided tumor therapy. Furthermore, we exhaustively reviewed the latest applications of multifunctional nano-phototherapy technologies carried out by NIR-II light including photothermal therapy (PTT), photodynamic therapy (PDT), and combined modalities like photothermal-chemodynamic therapy (PTT-CDT), photothermal-chemotherapy (PTT-CT), and photothermal- immunotherapy (PTT-IO). These imaging-guided integrated tumor therapy approaches within the NIR-II window have gradually matured over the past decade and are expected to become a safe and effective non-invasive tumor treatment. Finally, we outlined the prospects and challenges of development and innovation of the NIR-II integrated diagnosis and therapy nanoplatform. This review aims to provide insightful perspectives for future advancements in NIR-II optical tumor diagnosis and integrated treatment platforms.

4T1 Cell Membrane-Coated Pdots with NIR-II Absorption and Fluorescence Properties for Targeted Phototheranostics of Breast Tumors

Designing highly biocompatible organic semiconducting conjugated polymer dots (Pdots) with bright fluorescence and superior absorption properties in the second near-infrared window (NIR-II: 1000-1700 nm) remains a huge challenge for tumor phototheranostics. In this study, we constructed 4T1 cell membrane-coated m-PBTQ4F Pdots (CPdots) with enhanced NIR-II photoacoustic (PA) and fluorescence (FL) imaging capability for NIR-II photothermal therapy (PTT) of breast tumors. Our findings demonstrated that CPdots could specifically target breast tumors, leading to enhanced tumor accumulation after systemic administration in living mice. In addition, CPdots can not only serve as contrast agents for NIR-II PA and FL imaging for improved breast tumor detection but also generate more cytotoxic heat to improve PTT efficacy. Therefore, this pilot study opens an option avenue for developing new NIR-II Pdots with homologous targeting capability for enhanced phototheranostics of breast tumors.

NIR-II Orthogonal Fluorescent Ratiometric Nanoprobe for In Situ Bioimaging of Carbon Monoxide

Carbon monoxide (CO) functions as a significant endogenous cell signaling molecule and is strongly associated with many physiological and pathological processes. However, conventional fluorescence imaging in the visible and near-infrared (NIR) I regions suffers autofluorescence background and photon scattering, hindering the accurate detection of CO in vivo. In addition, the complexity of physiological environments leads to fluctuating fluorescence emission. To solve these problems, herein, the NIR-II fluorescent nanoprobe NP-Pd for in vivo ratiometric bioimaging of CO is developed. In the presence of CO, NP-Pd exhibits responsive enhancement in absorption at 808 nm, which amplifies the fluorescence signal of down-conversion nanoparticles (DCNP) at 1060 nm under 808 nm excitation, while the fluorescence signal of DCNP at 1525 nm under 980 nm excitation remains unchanged and serves as an internal standard. Through this orthogonally ratiometric fluorescence strategy, accurate CO bioimaging and precise diagnosis of acute liver injury diseases are achieved in the mouse model experiments, providing a novel tool for the in vivo detection of CO-related diseases.

Brain Targeting Nanomedicines: Pitfalls and Promise

Brain diseases are the most devastating problem among the world's increasingly aging population, and the number of patients with neurological diseases is expected to increase in the future. Although methods for delivering drugs to the brain have advanced significantly, none of these approaches provide satisfactory results for the treatment of brain diseases. This remains a challenge due to the unique anatomy and physiology of the brain, including tight regulation and limited access of substances across the blood-brain barrier. Nanoparticles are considered an ideal drug delivery system to hard-to-reach organs such as the brain. The development of new drugs and new nanomaterial-based brain treatments has opened various opportunities for scientists to develop brain-specific delivery systems that could improve treatment outcomes for patients with brain disorders such as Alzheimer's disease, Parkinson's disease, stroke and brain tumors. In this review, we discuss noteworthy literature that examines recent developments in brain-targeted nanomedicines used in the treatment of neurological diseases.

Biosynthesis of CuTe Nanorods with Large Molar Extinction Coefficients for NIR-II Photoacoustic Imaging

Photoacoustic imaging (PAI) in the second near-infrared region (NIR-II), due to deeper tissue penetration and a lower background interference, has attracted widespread concern. However, the development of NIR-II nanoprobes with a large molar extinction coefficient and a high photothermal conversion efficiency (PCE) for PAI and photothermal therapy (PTT) is still a big challenge. In this work, the NIR-II CuTe nanorods (NRs) with large molar extinction coefficients ((1.31 ± 0.01) × 108 cm-1·M-1 at 808 nm, (7.00 ± 0.38) × 107 cm-1·M-1 at 1064 nm) and high PCEs (70% at 808 nm, 48% at 1064 nm) were synthesized by living Staphylococcus aureus (S. aureus) cells as biosynthesis factories. Due to the strong light-absorbing and high photothermal conversion ability, the in vitro PA signals of CuTe NRs were about 6 times that of indocyanine green (ICG) in both NIR-I and NIR-II. In addition, CuTe NRs could effectively inhibit tumor growth through PTT. This work provides a new strategy for developing NIR-II probes with large molar extinction coefficients and high PCEs for NIR-II PAI and PTT.

Rotor-based image-guided therapy of glioblastoma

Glioblastoma (GBM), deep in the brain, is more challenging to diagnose and treat than other tumors. Such challenges have blocked the development of high-impact therapeutic approaches that combine reliable diagnosis with targeted therapy. Herein, effective cyanine dyes (IRLy) with the near-infrared two region (NIR-II) adsorption and aggregation-induced emission (AIE) have been developed via an "extended conjugation & molecular rotor" strategy for multimodal imaging and phototherapy of deep orthotopic GBM. IRLy was synthesized successfully through a rational molecular rotor modification with stronger penetration, higher signal-to-noise ratio, and a high photothermal conversion efficiency (PCE) up to ∼60%, which can achieve efficient NIR-II photo-response. The multifunctional nanoparticles (Tf-IRLy NPs) were further fabricated to cross the blood-brain barrier (BBB) introducing transferrin (Tf) as a targeting ligand. Tf-IRLy NPs showed high biosafety and good tumor enrichment for GBM in vitro and in vivo, and thus enabled accurate, efficient, and less invasive NIR-II multimodal imaging and photothermal therapy. This versatile Tf-IRLy nanosystem can provide a reference for the efficient, precise and low-invasive multi-synergistic brain targeted photo-theranostics. In addition, the "extended conjugation & molecular rotor" strategy can be used to guide the design of other photothermal agents.

NIR-II Conjugated Electrolytes as Biomimetics of Lipid Bilayers for In Vivo Liposome Tracking

Liposomes serve as promising and versatile vehicles for drug delivery. Tracking these nanosized vesicles, particularly in vivo, is crucial for understanding their pharmacokinetics. This study introduces the design and synthesis of three new conjugated electrolyte (CE) molecules, which emit in the second near-infrared window (NIR-II), facilitating deeper tissue penetration. Additionally, these CEs, acting as biomimetics of lipid bilayers, demonstrate superior compatibility with lipid membranes compared to commonly used carbocyanine dyes like DiR. To counteract the aggregation-caused quenching effect, CEs employ a twisted backbone, as such their fluorescence intensities can effectively enhance after a fluorophore multimerization strategy. Notably, a "passive" method was employed to integrate CEs into liposomes during the liposome formation, and membrane incorporation efficiency was significantly promoted to nearly 100%. To validate the in vivo tracking capability, the CE-containing liposomes were functionalized with cyclic arginine-glycine-aspartic acid (cRGD) peptides, serving as tumor-targeting ligands. Clear fluorescent images visualizing tumor site in living mice were captured by collecting the NIR-II emission. Uniquely, these CEs exhibit additional emission peak in visible region, enabling in vitro subcellular analysis using routine confocal microscopy. These results underscore the potential of CEs as a new-generation of membrane-targeting probes to facilitate the liposome-based medicine research.

Near-infrared dye IRDye800CW-NHS coupled to Trastuzumab for near-infrared II fluorescence imaging in tumor xenograft models of HER-2-positive breast cancer

Near-infrared II fluorescent probes targeting tumors for diagnostic purposes have received much attention in recent years. In this study, a fluorescent probe for the NIR-II was constructed by using IRDye800CW-NHS fluorescent dye with Trastuzumab, which was investigated for its ability to target HER-2-positive breast cancer in xenograft mice models. This probe was compared with Trastuzumab-ICG which was synthesized using a similar structure, ICG-NHS. The results demonstrated that the IRDye800CW-NHS had significantly stronger fluorescence in the NIR-I and NIR-II than ICG-NHS in the aqueous phase. And the different metabolic modes of IRDye800CW-NHS and ICG-NHS were revealed in bioimaging experiments. IRDye800CW-NHS was mainly metabolised by the kidneys, while ICG-NHS was mainly metabolised by the liver. After coupling with Trastuzumab, Trastuzumab-800CW (TMR = 5.35 ± 0.39) not only had a stronger tumor targeting ability than Trastuzumab-ICG (TMR = 4.42 ± 0.10) based on the calculated maximum tumor muscle ratio (TMR), but also had a comparatively lower hepatic uptake and faster metabolism. Histopathology analysis proved that both fluorescent probes were non-toxic to various organ tissues. These results reveal the excellent optical properties of IRDye800CW-NHS, and the great potential of coupling with antibodies to develop fluorescent probes that will hopefully be applied to intraoperative breast cancer navigation in humans.

Recent Progress in NIR-II Fluorescence Imaging-guided Drug Delivery for Cancer Theranostics

Fluorescence imaging in the second near-infrared window (NIR-II) has become a prevalent choice owing to its appealing advantages like deep penetration depth, low autofluorescence, decent spatiotemporal resolution, and a high signal-to-background ratio. This would expedite the innovation of NIR-II imaging-guided drug delivery (IGDD) paradigms for the improvement of the prognosis of patients with tumors. This work systematically reviews the recent progress of such NIR-II IGDD-mediated cancer therapeutics and collectively brings its essence to the readers. Special care has been taken to assess their performances based on their design approach, such as enhancing their drug loading and triggering release, designing intrinsic and extrinsic fluorophores, and/ or overcoming biological barriers. Besides, the state-of-the-art NIR-II IGDD platforms for different therapies like chemo-, photodynamic, photothermal, chemodynamic, immuno-, ion channel, gas-therapies, and multiple functions such as stimulus-responsive imaging and therapy, and monitoring of drug release and therapeutic response, have been updated. In addition, for boosting theranostic outcomes and clinical translation, the innovation directions of NIR-II IGDD platforms are summarized, including renal-clearable, biodegradable, sub-cellular targeting, and/or afterglow, chemiluminescence, X-ray excitable NIR-IGDD, and even cell therapy. This review will propel new directions for safe and efficient NIR-II fluorescence-mediated anticancer drug delivery.

Maximal emission beyond 1200 nm dicyanovinyl-functionalized squaraine for in vivo vascular imaging

The first maximum emission wavelength beyond 1200 nm acceptor-substituted squaraine fluorophore with ultra-high brightness and photostability has been developed. It can be co-assembled with bovine serum albumin to form an excellent biocompatible dye-protein nanocomplex with significant fluorescence enhancement for high-resolution vascular imaging.